MPM Bioventures 2018, L.P., 10% Owner at Aktis Oncology, Inc. (AKTS), bought 1,112,777 shares at $18.00 ($20.0M) on 2026-01-12, disclosed to the SEC on 2026-01-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| Filing → |
| TRDA | SELL | 2026-08-31 | $616K | — | Filing → |
| TRDA | SELL | 2026-08-26 | $462K | — | Filing → |
| ITOS | SELL | 2021-12-07 | $3.3M | — | Filing → |